845 related articles for article (PubMed ID: 32141018)
21. A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy.
Capri S; Migliore A; Loconsole F; Barbieri M
J Med Econ; 2020 Apr; 23(4):353-361. PubMed ID: 31856609
[No Abstract] [Full Text] [Related]
22. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
Vanderpoel J; Tkacz J; Brady BL; Ellis L
Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662
[TBL] [Abstract][Full Text] [Related]
23. Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
Schwartzman S; Li Y; Zhou H; Palmer JB
Clin Rheumatol; 2017 Jul; 36(7):1579-1588. PubMed ID: 28474139
[TBL] [Abstract][Full Text] [Related]
24. Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.
Poulin Y; Beauchemin C; Royer C; Gaudreau AJ; Yim C; Liu FF; Lachaine J
J Cutan Med Surg; 2020; 24(6):573-587. PubMed ID: 32597685
[TBL] [Abstract][Full Text] [Related]
25. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
J Dermatolog Treat; 2021 Mar; 32(2):203-211. PubMed ID: 31769703
[TBL] [Abstract][Full Text] [Related]
26. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
[TBL] [Abstract][Full Text] [Related]
27. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice.
Gratacós-Masmitja J; Beltrán Catalán E; Álvarez Vega JL; Urruticoechea-Arana A; Fito C; Maceiras F; Belzunegui Otano JM; Fernández Melón J; Chamizo Carmona E; Abad Hernández MÁ; Ros Vilamajó I; Castro Oreiro S; Pascual Alfonso E; Torre Alonso JC;
Reumatol Clin (Engl Ed); 2024 Jan; 20(1):24-31. PubMed ID: 38233009
[TBL] [Abstract][Full Text] [Related]
28. Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland.
Koskivirta I; Ruotsalainen J; Kurki S; Lakkakorpi P; Salminen-Mankonen H; Pirilä L; Harvima R; Palomäki A
Scand J Rheumatol; 2023 Sep; 52(5):549-555. PubMed ID: 36644971
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
[TBL] [Abstract][Full Text] [Related]
30. The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids.
Persson R; Hagberg KW; Qian Y; Vasilakis-Scaramozza C; Jick S
Rheumatology (Oxford); 2021 Apr; 60(4):1926-1931. PubMed ID: 33159794
[TBL] [Abstract][Full Text] [Related]
31. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients.
Favalli EG; Conti F; Selmi C; Iannone F; Bucci R; D'Onofrio F; Carlino G; Santo L; Semeraro A; Zuccaro C; D'Angelo S; Atzeni F; Marino F; Monti S; Guidelli GM; Spinelli FR; Biggioggero M; Caporali R
Clin Exp Rheumatol; 2020; 38(1):19-26. PubMed ID: 31074721
[TBL] [Abstract][Full Text] [Related]
32. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
Curtis JR; Chastek B; Becker L; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier DH
J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
[TBL] [Abstract][Full Text] [Related]
33. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
34. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
35. Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database.
Husni ME; Chang E; Broder MS; Paydar C; Bognar K; Desai P; Klyachkin Y; Khilfeh I
Open Access Rheumatol; 2022; 14():123-132. PubMed ID: 35734243
[TBL] [Abstract][Full Text] [Related]
36. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database.
Mease PJ; Young P; Gruben D; Fallon L; Germino R; Kavanaugh A
Adv Ther; 2022 Jun; 39(6):2932-2945. PubMed ID: 35482248
[TBL] [Abstract][Full Text] [Related]
37. Apremilast and its role in psoriatic arthritis.
Sandhu VK; Eder L; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
[TBL] [Abstract][Full Text] [Related]
38. Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis.
Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Hoit Marchlewicz E; Shrady G; Zhao Y; Mendelsohn AM
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755976
[TBL] [Abstract][Full Text] [Related]
39. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
40. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
